The European Medicines Agency has granted Investigational Medicinal Product Dossier approval to Emercell for its allogeneic natural killer cell therapy targeting diffuse large B-cell lymphoma.
The NK cell therapy market is experiencing robust growth driven by increasing interest in immuno-oncology and advancements in cell engineering technologies, with significant expansion expected through 2034.
Chonnam National University Hwasun Hospital and VaxCell Biotherapeutics receive approval for advanced regenerative medicine study combining NK cell therapy VCB-1102 with standard chemotherapy for pancreatic cancer.
A Phase I clinical trial evaluated the safety and efficacy of allogeneic natural killer (NK) cell therapy in children with relapsed or refractory neuroblastoma.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.